Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors

10. november 2026 opdateret af: CStone Pharmaceuticals

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).

In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

310

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • New South Wales
      • North Ryde, New South Wales, Australien, 2109
        • Macquarie University
        • Ledende efterforsker:
          • John Park, Dr
      • Randwick, New South Wales, Australien, 2031
        • Scientia Clinical Research Ltd
        • Ledende efterforsker:
          • Charlotte lemech, Dr
    • Victoria
      • Clayton, Victoria, Australien, 3168
        • Monash Medical Centre
        • Ledende efterforsker:
          • Sophia Frentzas, Dr
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200123
        • Shanghai East Hospital
        • Ledende efterforsker:
          • Caicun Zhou

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Being ≥ 18 years of age on the day of signing informed consent.
  • Pathologically or cytologically confirmed, unresectable advanced solid tumors.
  • Participants must have at least one measurable lesion according to RECIST Version1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
  • Adequate organ function.
  • Life expectancy ≥ 3 months.
  • Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration

Exclusion Criteria:

  • Has disease that is suitable for local treatment administered with curative intent.
  • Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
  • Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites.
  • Has immune deficient disease or received systemic immunosuppressive treatment.
  • Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
  • Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
  • Has active infections requiring systemic therapy.
  • Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
  • Insufficient washout from prior anti-tumor therapy.
  • Received live vaccine within 28 days prior to first dose.
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • History of hypersensitivity to excipients of study drug or any monoclonal antibody.
  • Any toxic effects of prior therapy unresolved to Grade ≤1.
  • Pregnant or breastfeeding women.
  • Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose Escalation

Participants will be administered escalating doses of CS5006.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Eksperimentel: Dose Expansion

Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
[Dosisudvidelse] Objektiv responsrate (ORR) evalueret af efterforskere pr. RECIST v1.1
Tidsramme: Op til cirka 2 år
Op til cirka 2 år
[Dose Escalation] The incidence and severity of adverse events (AEs)
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Tidsramme: Cycle 1 (Up to 21 Days)

Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).

Cycle 1 (Up to 21 Days)
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Tidsramme: Up to approximately 2 years

The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.

Up to approximately 2 years

Sekundære resultatmål

Resultatmål
Tidsramme
[Dosiseskalering] Objektiv responsrate (ORR) evalueret af efterforskere pr. RECIST v1.1
Tidsramme: Op til cirka 2 år
Op til cirka 2 år
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Expansion] The incidence and severity of adverse events (AEs)
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Tidsramme: Up to approximately 2 years
Up to approximately 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. juli 2029

Studieafslutning (Anslået)

1. juli 2029

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CS5006-101

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner